<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844983</url>
  </required_header>
  <id_info>
    <org_study_id>SRN-705-008</org_study_id>
    <nct_id>NCT04844983</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirnaomics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sirnaomics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate safety, tolerability and efficacy of various doses&#xD;
      of STP705 administered as intralesional injection in subjects with cutaneous squamous cell&#xD;
      carcinoma (in situ) skin cancer (isSCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part, double-blind, randomized, placebo-controlled study designed to evaluate&#xD;
      safety and efficacy of various doses of STP705 administered as an intralesional injection in&#xD;
      subjects with isSCC.&#xD;
&#xD;
      A total of up to 100 eligible subjects will be enrolled. Enrolled subjects will be randomly&#xD;
      allocated to receive STP705 or placebo injection once weekly for 6 weeks.&#xD;
&#xD;
      After 6 weeks, the lesion will be excised.&#xD;
&#xD;
      In part 1 (dose ranging study): 40 subjects will be randomized to receive 1 of the 3 STP705&#xD;
      doses or placebo.&#xD;
&#xD;
      An interim analysis will be done after all subjects have completed end of treatment (EOT)&#xD;
      visits to determine 2 selected dose levels of STP705 to be used in part of the study.&#xD;
&#xD;
      In part 2: 60 additional subjects will be randomized to receive 1 of the 2 selected doses&#xD;
      (from part 1) or placebo.&#xD;
&#xD;
      In both parts at the End of Treatment (EOT), the lesion will be excised.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part 1: 40 subjects randomized in a 1:1:1:1 ratio to receive 6 weeks of treatment of placebo, 30 ug, 60 ug, or 90 ug of STP705. Enrollment will be temporarily stopped after the 40th subject. Interim Analysis will be done for dose response assessment and selection of the 2 doses for Part 2 of the study.&#xD;
Part 2: 60 additional subjects will be randomized in a 1:1:1 ratio to receive placebo or one of the 2 selected STP705 doses.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a double-blind study. All subjects, investigators, and site staff (except unblinded pharmacist or designated site staff) in the study will be blinded to the treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with histological clearance of treated isSCC lesion</measure>
    <time_frame>6 weeks</time_frame>
    <description>Proportion of participants with histological clearance of treated isSCC lesion at the End of Treatment (EOT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in size of the treated isSCC lesion</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in size of the treated isSCC lesion over the 6-week treatment period.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Squamous Cell Carcinoma in Situ</condition>
  <arm_group>
    <arm_group_label>Part 1: Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STP705 30 μg dose, intralesional injection, given once a week for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STP705 60 μg dose, intralesional injection, given once a week for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STP705 90 μg dose, intralesional injection, given once a week for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Arm D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo (normal saline), intralesional injection, given once a week for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm A, B or C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STP705 selected dose 1, intralesional injection, given once a week for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm A or B or C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STP705 selected dose 2, intralesional injection, given once a week for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Arm D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo (normal saline), intralesional injection, given once a week for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STP705</intervention_name>
    <description>The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.</description>
    <arm_group_label>Part 1: Arm A</arm_group_label>
    <arm_group_label>Part 1: Arm B</arm_group_label>
    <arm_group_label>Part 1: Arm C</arm_group_label>
    <arm_group_label>Part 2: Arm A or B or C</arm_group_label>
    <arm_group_label>Part 2: Arm A, B or C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Saline</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Part 1: Arm D</arm_group_label>
    <arm_group_label>Part 2: Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female adult ≥ 18 years of age.&#xD;
&#xD;
          2. Primary, histologically confirmed trunk or extremity (non- anogenital/-facial/-scalp)&#xD;
             isSCC lesion suitable for excision with a minimum diameter of 0.5 cm and with a&#xD;
             maximum diameter of 2.0 cm.&#xD;
&#xD;
          3. Histological diagnosis made no more than 6 months prior to the screening visit.&#xD;
&#xD;
          4. No other dermatological disease in the isSCC target site or surrounding area, which in&#xD;
             the opinion of the investigator, could interfere with the study.&#xD;
&#xD;
          5. Willing to refrain from using non-approved lotions or creams on the target site and&#xD;
             surrounding area during the treatment period.&#xD;
&#xD;
          6. Willing to refrain from exposure to excessive direct sunlight or ultraviolet light and&#xD;
             to avoid the use of tanning parlors for the duration of the study.&#xD;
&#xD;
          7. Laboratory values for the tests (listed in the Study Schedule) within the reference&#xD;
             ranges as defined by the central laboratory, or &quot;out of range&quot; test results that are&#xD;
             clinically acceptable to the investigator.&#xD;
&#xD;
          8. Ability to follow study instructions and likely to complete all study requirements.&#xD;
&#xD;
          9. Written informed consent obtained, including consent for tissue to be examined and&#xD;
             stored by the Central Histology Lab.&#xD;
&#xD;
         10. Written consent to allow photographs of the target isSCC lesion to be used as part of&#xD;
             the study data and documentation.&#xD;
&#xD;
         11. For females of childbearing potential, a negative pregnancy test at screening and&#xD;
             using an acceptable form of birth control (oral / implant/ injectable/ transdermal&#xD;
             contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous&#xD;
             relationship with a partner who has had a vasectomy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant, lactating, or planning to become pregnant.&#xD;
&#xD;
          2. Presence of known or suspected systemic cancer.&#xD;
&#xD;
          3. Histological evidence of severe squamous metaplasia, infiltrative, desmoplastic or&#xD;
             micronodular growth patterns in the biopsy specimen.&#xD;
&#xD;
          4. History of recurrence of the target isSCC lesion.&#xD;
&#xD;
          5. Concurrent disease or treatment that suppresses the immune system.&#xD;
&#xD;
          6. Patients with baseline QTC &gt; 480 msec using Frederica's formula.&#xD;
&#xD;
          7. Chronic medical condition that in the judgment of the investigator(s) would interfere&#xD;
             with the performance of the study or would place the patient at undue risk.&#xD;
&#xD;
          8. Known sensitivity to any of the ingredients in the study medication including an&#xD;
             allergy to trehalose.&#xD;
&#xD;
          9. Use of a tanning bed or other excessive or prolonged exposure to ultraviolet light or&#xD;
             direct sunlight during the study.&#xD;
&#xD;
         10. Treatment with systemic chemotherapeutic agents within the 6 months prior to the&#xD;
             screening visit.&#xD;
&#xD;
         11. Use of systemic retinoids within the 6 months prior to the screening period.&#xD;
&#xD;
         12. Treatment with systemic immunomodulators or immunosuppressants within the 6 months&#xD;
             prior to the screening period.&#xD;
&#xD;
         13. Use of topical immunomodulators within 2 cm of the target isSCC lesion within the 4&#xD;
             weeks prior to the screening period.&#xD;
&#xD;
         14. Treatment with the following topical agents within 2 cm of the target isSCC lesion&#xD;
             within the 4 weeks prior to the screening visit: aminolevulinic acid, 5-fluorouracil,&#xD;
             corticosteroids, retinoids, diclofenac, ingenol mebutate, or imiquimod.&#xD;
&#xD;
         15. Treatment with liquid nitrogen, surgical excision or curettage within 2 cm of the&#xD;
             target isSCC lesion during the 4 weeks prior to the screening visit.&#xD;
&#xD;
         16. Evidence of current chronic alcohol or drug abuse.&#xD;
&#xD;
         17. Current enrollment in an investigational drug or device study or participation in such&#xD;
             a study within 4 weeks of the screening visit.&#xD;
&#xD;
         18. In the investigator's opinion, evidence of unwillingness, or inability to follow the&#xD;
             restrictions and requirements of the protocol and complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nadia Sheibani</last_name>
    <phone>301-740-1730</phone>
    <email>nadiasheibani@sirnaomics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Investigate</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>480-440-5985</phone>
    </contact>
    <investigator>
      <last_name>Brenda La Towsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Clinical and Cosmetic Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-933-6716</phone>
    </contact>
    <investigator>
      <last_name>Mark Nestor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute of the Southeast LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-655-9055</phone>
    </contact>
    <investigator>
      <last_name>Kenneth Beer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schweiger Dermatology</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>609-219-5621</phone>
    </contact>
    <investigator>
      <last_name>David Goldberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Edward Primka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-383-9660</phone>
    </contact>
    <investigator>
      <last_name>Michael Gold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-279-2545</phone>
    </contact>
    <investigator>
      <last_name>Edward Lain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

